Boron Neutron Capture Therapy for Cancer: Current Status and Future Prospects

Dear Colleagues,

Boron neutron capture therapy has entered a new era with the commercialization of accelerator neutron sources. This special issue will cover the status of accelerator development, which has entered the practical stage, the clinical treatment for recurrent head and neck cancer initiated in Japan, new findings found by reactor therapy, and clinically relevant reviews. We also invite papers on malignant glioma, studies on new target diseases, principles and validation of newly developed neutron sources, and new findings on treatment simulation systems.

Prof. Dr. Hideyuki Sakurai
Dr. Hiroaki Kumada
Dr. Kei Nakai
Dr. Yoshitaka Matsumoto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Dr. Yoshitaka Matsumoto
Dr. Kei Nakai
Prof. Dr. Hideyuki Sakurai
Dr. Hiroaki Kumada
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• boron neutron capture therapy
• accelerator
• reactor
• boron
• neutron
• radiation therapy
• particle radiation therapy
• cancer treatment
• recurrent head and neck cancer
• malignant brain tumor
• skin tumor